Study finds omalizumab relieves seasonal asthma attacks in youth

A drug that targets the antibody immunoglobulin E (IgE), a key player in asthma, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner city environments, a clinical trial sponsored by the National Institutes of Health has found.

Read the whole article on Physorg

More from Physorg